Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.1K
Overview
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same author

Vaccine-Preventable Disease Control in the WHO African Region After the COVID-19 Public Health Emergency of International Concern: Implications for Recovery, Resilience, and System Transformation.

Vaccines·2026
Same author

Exploring the Contextual Factors That Influence Polio Supplementary Immunisation Activities in the WHO African Region: A Rapid Review.

Vaccines·2025
Same author

Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.

Vaccines·2024
Same author

Progress with the Second Dose Measles Vaccine Introduction and Coverage in the WHO African Region.

Vaccines·2024
Same author

Exploring Important Attributes, the Potential Use Cases and Feasibility of Introduction of Measles and Rubella Microarray Patches (MR-MAPs): Insights from Nine Countries.

Vaccines·2024

Related Experiment Video

Updated: Jun 11, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000-2023, Namibia.

Balcha G Masresha1, Messeret E Shibeshi1, Roselina de Wee2

  • 1African Regional Office, World Health Organization, Brazzaville P.O. Box 06, Congo.

Vaccines
|September 28, 2024
PubMed
Summary

Namibia

Keywords:
Namibiaeliminationincidencemeaslesrubella

More Related Videos

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
09:13

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Published on: November 1, 2011

17.4K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K

Related Experiment Videos

Last Updated: Jun 11, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K
Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
09:13

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Published on: November 1, 2011

17.4K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K

Area of Science:

  • Public Health
  • Epidemiology
  • Vaccinology

Background:

  • Namibia's commitment to measles and rubella elimination aligns with the WHO Measles and Rubella Strategic Framework 2021-2030.
  • The country has been actively implementing measles elimination strategies since 1997.

Purpose of the Study:

  • To describe the implementation of measles and rubella elimination strategies in Namibia from 2000-2023.
  • To assess the programmatic and epidemiological impact of these strategies, including the introduction of the rubella-containing vaccine (RCV).

Main Methods:

  • Review of implementation strategies for measles and rubella elimination.
  • Analysis of programmatic and epidemiological data from 2000-2023.
  • Inclusion of data on vaccination coverage, case-based surveillance, outbreak investigations, and serosurveys.

Main Results:

  • Measles-containing vaccine (MCV1) coverage reached 90% in 2020 and was sustained above 90% through 2022.
  • Measles-rubella (MR) vaccination coverage (MCV2) increased to 79% by 2022 after its 2016 introduction.
  • Annual measles and rubella incidence significantly decreased by 97% and 95% respectively between 2017-2023 compared to 2010-2016, following the 2016 MR catch-up campaign.

Conclusions:

  • High routine immunization coverage and the 2016 MR catch-up campaign significantly reduced measles and rubella incidence in Namibia.
  • Sustaining high coverage of both MR vaccine doses and conducting timely follow-up campaigns are crucial for elimination.
  • Robust surveillance systems are essential for guiding strategies and verifying elimination.